TrialArthritis & rheumatology (Hoboken, N.J.)2018

Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.